CorPath® System, RaySafe i2 product alignment identifies real-time radiation exposure for better dose protection during robotic-assisted procedures
Waltham, MA and Everett, WA – August 18, 2015 – Corindus Vascular Robotics, Inc.[NYSE MKT: CVRS], a leading developer of precision vascular robotics, and Unfors RaySafe, Inc., a Fluke Biomedical Company, today announced a distribution agreement allowing Corindus to offer the RaySafe i2 real-time radiation dose monitoring system in conjunction with the CorPath System, enabling catheterization lab physicians and staff to better protect themselves from, and monitor for, excessive radiation exposure.
The interventional cardiology field is increasingly concerned about the cumulative effects of radiation exposure on physicians and cath lab staff as more studies emerge and stories of individuals who have been forced to leave practice become more prevalent. The 95% radiation exposure reduction1,2 afforded by the CorPath System’s radiation shielded cockpit increases protection for interventional cardiologists, while the RaySafe i2 badge worn by cath lab workers displays radiation exposure levels in real-time allowing the team to be more aware of exposure levels and take steps to minimize exposure, while continuing to deliver a high standard of care.
“As more studies emerge, the push for improved standards of safety in interventional cardiology is increasing, with radiation protection for the healthcare providers at the center of it,” stated Tal Wenderow, Co-Founder, Executive Vice President Product & Business Development, Corindus Vascular Robotics. “With today’s available robotic and dose monitoring technologies, there is no reason for cath lab staff to be exposed to any more than the absolute minimum radiation that is required. It is important that our industry supports those that provide care to patients, which is why we chose to partner with RaySafe. Our objectives are similar: to empower and protect cath lab physicians and staff with the safety afforded by new technologies.“
Spectrum Health System, based in Grand Rapids, Mich., is one of the first facilities in the U.S. to install and jointly utilize the CorPath System and RaySafe i2. “We take significant measures to protect our patients, and through the addition of these products, we can do the same for our physicians and cath lab staff“, stated Ryan Madder, MD, interventional cardiologist at Spectrum Health. “Having integrated the products into my daily practice, I am more aware of both my own exposure levels and that of my team. I appreciate how these technologies can significantly change our behaviors and put us in a safer position to perform procedures.“
“Unfors RaySafe’s mission is to help medical staff avoid unnecessary radiation exposure and establish a stronger radiation safety culture,“ stated Chintan Shah, Marketing and Sales Manager, Unfors RaySafe. “Our collaboration with Corindus aligns with this focus. Together, our solutions will allow physicians and their staff to create a safer work environment in interventional cardiology and radiology labs where they are exposed to higher radiation doses. The reduction of radiation exposure for staff is top-of-mind, and the combination of these two products provides a new level of safety in the cath lab.“
1Weisz, G. et al., Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J Am Coll Cardiol. 2013;61(15):1596-1600.
2PRECISE Study sponsored by Corindus, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: